MediWound
CompanyIsrael
MediWound develops one asset, in phase 2 (EscharEx in venus leg ulcers). Mostly protein or enzyme; based in Israel.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Bromelain-based proteolytic enzymes remove devitalized tissue from chronic wounds through enzymatic debridement.
Phase 2, Protein or enzyme, venus leg ulcers
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals1